Mon. 8 Apr 2024, 2:54am ET
Benzinga
News
- - Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
- - SHASTA-3 and SHASTA-4 Phase 3 studies to be initiated